Abstract:The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development. Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents. The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion. In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending. As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment. Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells. We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies. Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future.

Macrophage colony-stimulating factor and its role in the tumor microenvironment: novel therapeutic avenues and mechanistic insights

Interactions Between Colon Cancer Cells and Tumor-Infiltrated Macrophages Depending on Cancer Cell-Derived Colony Stimulating Factor 1

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Crosstalk between Tumor-Associated Macrophages and MicroRNAs: A Key Role in Tumor Microenvironment

Advances in the Macrophages and Their Interaction with Tumor Cells

The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression

Macrophage crosstalk and therapies: Between tumor cells and immune cells

Tumor-associated macrophages within the immunological milieu: An emerging focal point for therapeutic intervention

Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance

Tumor-Associated Macrophages: Recent Insights and Therapies

Insights into CSF-1R Expression in the Tumor Microenvironment

Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer

Roles of Tumor-Associated Macrophages in Tumor Environment and Strategies for Targeting Therapy

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment

Research Progress on the Role of Tumor‑associated Macrophages in Tumor Development and Their Use As Molecular Targets (Review).

Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy

New insights into the role of macrophages in cancer immunotherapy

Role of chemokines in the crosstalk between tumor and tumor-associated macrophages

Microenvironmental regulation in tumor progression: Interactions between cancer-associated fibroblasts and immune cells

Advances in tumor immunotherapy targeting macrophages